Momelotinib (Ojjaara)
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. Momelotinib competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells.
Diseases for which it is established
History of changes in FDA indication
- 2023-09-15: Approved for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. (Based on MOMENTUM & SIMPLIFY-1)
History of changes in EMA indication
- 2024-01-24: Initial authorization as Omjjara. Omjjara is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor naive or have been treated with ruxolitinib. (Based on MOMENTUM & SIMPLIFY-1)
Also known as
- Code names: CYT-387, GS-0387
- Brand name: Ojjaara, Omjjara